BioSerenTach Inc –{•¶‚ÖƒWƒƒƒ“ƒv
BioSerenTach has the following innovative three DDS technologies.

The possible clients are pharmaceutical companies.

BioSerenTach performs pre-clinical study and clinical phase I study
with the clients.

Dissolving Microneedle (DM) chip

DM is a novel transdermal DDS. DM is composed of water-soluble thread-forming polymer and drug that exists as solid dispersion or suspension. 100-300 microneedles are formed on a chip, 1.0 c‡u, where the length is 500ƒÊm and the diameter of the base is 300ƒÊm. As polymer, chondroitin sulfate, sodium hyarulonate, dextran and albumin are used. Drug is localized at the acral portion of microneedles. After insertion into the skin by pressing with a finger, polymer dissolves in the epiderm and drug is immediately released and absorbed into the systemic circulation. As a drug, vaccine antigen, insulin, erythropoietin (EPO), interferon (IFN) and growth hormone (GH) are recommended.

see details of our technologies

Gastrointestinal mucoadhesive patch system

GI-MAPS is especially recommended to
glycoprotein drugs like EPO and G-CSF.

see details of our technologies

Three-layered microcapsules

For a long-term sustained-release injection preparation of leuprolide acetate, insulin, calcitonin, IFN, EPO, G-CS and GH etc
Microcapsules composed of three layers, (1) surface layer, (2) drug-carrying layer and (3) basement, have been developed. The surface layer has a function of controlling the release rate of drug. By selecting the compostion of the surface layer, long-term sustained-release injection preparation, for example one month, is prepared. Feasibility study was performed with EPO, leuprolide acetate and low molecular weight heparin (LMWH) with poly-ƒÃ-caprolactone and sustained-release charactersitics for about 10 days was ascertained in rat experiments. BioSerenTach is now developing a machine to produce three-layered microcapsules.


Copyright BioSerenTach Inc, 2021